Clinical Report: Building a Pre-Disease Data Map

Overview

Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC, to study biological changes that precede disease symptoms. The initiative plans to generate molecular data from up to one million biospecimens and link proteomic and genomic findings with longitudinal clinical information, using AI and large-scale analytics to identify patterns.

Background

Precure is intended to complement Mayo Clinic’s investigator-led Precure Research program, which focuses on the transition from health to disease. The company aims to provide infrastructure and scale for population-level molecular datasets and external collaborations. Its stated areas of interest include cancer, cardiometabolic disease, neurological disorders, and immune-mediated conditions. In a related area, the National Cancer Institute’s Cancer Screening Research Network is conducting the Vanguard Study to assess the feasibility of multi-cancer detection blood tests and inform the design of definitive trials.

Data Highlights

Key Findings

• Precure’s stated goal is to identify biological changes that occur before disease symptoms emerge.
• The initiative plans to generate molecular data from up to one million biospecimens and connect these data with clinical information collected over several years.
• Advanced AI and large-scale data analytics are planned to identify patterns in the resulting datasets.
• Thermo Fisher will contribute proteomics expertise and technologies, including the Olink Explore HT platform and Thermo Scientific Orbitrap Mass Spectrometry.
• Mayo Clinic says financial returns from the venture will be reinvested in its nonprofit missions of patient care, research, and education.
• The NCI Vanguard Study is a separate feasibility effort evaluating multi-cancer detection blood tests to inform the design of definitive randomized trials.

Clinical Implications

The company describes the dataset as a resource for research into earlier diagnosis, targeted interventions, and therapeutic strategies; these are stated aims, not reported clinical outcomes. The related NCI Vanguard Study is evaluating the feasibility of multi-cancer detection testing, rather than establishing its clinical effectiveness.

Conclusion

Precure is a planned population-scale multi-omics initiative focused on the biology preceding symptoms. Its proposed dataset and analytics are intended to support research into disease development and potential diagnostic and therapeutic applications.

Related Resources & Content

1. Mayo Clinic and Thermo Fisher Scientific, PR Newswire, 2026 — Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear
2. National Cancer Institute, 2026 — Questions and Answers about the Vanguard Study
3. ASCO Publications, 2026 — Building a real-time cancer data mart (CDM) for an integrated health system, leveraging traditional natural language processing (NLP) methods, curated data sources, and large language models (LLMs)
4. ASCO Publications — Building a real-time cancer data mart (CDM) for an integrated health system, leveraging traditional natural language processing (NLP) methods, curated data sources, and large language models (LLMs).
5. ASCO Publications — Building a real-time cancer data mart (CDM) for an integrated health system, leveraging traditional natural language processing (NLP) methods, curated data sources, and large language models (LLMs).
6. ASCO Publications — Building the Human Infrastructure for Cancer Data Reuse
7. Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear
8. Questions and Answers about the Vanguard Study - NCI
9. Building a real-time cancer data mart (CDM) for an integrated health system
10. Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear
11. Questions and Answers about the Vanguard Study - NCI
12. Next-generation multi-cancer early detection (MCED) assay: Independent blinded validation of a locked serum multi-omics NMR test with stage I sensitivity. | Journal of Clinical Oncology
13. V1.0 Jan 2026
14. Advancing AI for multi-omics and clinical data integration in basic and translational cancer research | Nature Reviews Cancer